Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | FLT3 | P36888 | 3/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.38 |
| ▸ | METAP2 | P50579 | 5/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769117 | 1.00 | TRPA1 (0.47) | TRPA1IDO1AXLNOS1CDK2 | |
| SCHEMBL8404436 | 0.79 | IDO1 (0.46) | TRPA1IDO1AXLNOS1CDK2 | |
| SCHEMBL31411470 | 0.79 | TRPA1 (0.50) | TRPA1IDO1AXLNOS1CDK2 | |
| SCHEMBL7918824 | 0.76 | IDO1 (0.43) | TRPA1IDO1AXLNOS1CDK2 | |
| SCHEMBL5019954 | 0.76 | TRPA1 (0.47) | TRPA1IDO1AXLNOS1CDK2 | |
| SCHEMBL3534803 | 0.76 | MAPT (0.52) | IDO1AXLNOS1CDK2CCNA1 | |
| SCHEMBL19657811 | 0.76 | NOS1 (0.50) | TRPA1IDO1AXLNOS1CDK2 | |
| SCHEMBL22160446 | 0.76 | NOS1 (0.55) | TRPA1IDO1AXLNOS1CDK2 | |
| SCHEMBL16178599 | 0.76 | TRPA1 (0.47) | TRPA1IDO1AXLNOS1CDK2 | |
| SCHEMBL5421701 | 0.76 | TRPA1 (0.47) | TRPA1IDO1AXLNOS1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| WO-2023274246-A1 | AMIDE COMPOUND AND USE THEREOF | 成都分迪药业有限公司 | 2023-01-05 | — | — | WO | disclosed |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| WO-2020016235-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS | MERCK PATENT GMBH (DE) | 2020-01-23 | — | — | WO | disclosed |
| WO-2019001572-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | 北京泰德制药股份有限公司 | 2019-01-03 | — | — | WO | disclosed |
| EP-3421465-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2019-01-02 | — | — | EP | disclosed |
| WO-2018130853-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS | SALVENSIS (GB) | 2018-07-19 | — | — | WO | disclosed |
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | TRPA1 3323/4885IDO1 1106/4885AXL 38/4885 |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | DLD, GCDH, DLAT | TRPA1 4694/4885IDO1 1096/4885AXL 4839/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | TRPA1 1687/4885IDO1 1936/4885AXL 3079/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | TRPA1 63/4885IDO1 3035/4885AXL 4111/4885 |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | MET, DMPK, RET | TRPA1 3981/4885IDO1 3697/4885AXL 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.